Antitumor activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone.

Diletta Bianchini; David Lorente; Alejo Rodriguez-Vida; Aurelius Omlin; Carmel Jo Pezaro; Roberta Ferraldeschi; Andrea Zivi; Gerhardt Attard; Simon Chowdhury; Johann S De Bono

doi:10.1016/j.ejca.2013.08.020

Antitumor activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone.

Diletta Bianchini, David Lorente, Alejo Rodriguez-Vida, Aurelius Omlin, Carmel Jo Pezaro, Roberta Ferraldeschi, Andrea Zivi, Gerhardt Attard, Simon Chowdhury, Johann S De Bono

Research output: Contribution to journal › Article › Research › peer-review

184 Citations (Scopus)

Original language	English
Pages (from-to)	78-84
Number of pages	7
Journal	European Journal of Cancer
Volume	50
Issue number	1
DOIs	https://doi.org/10.1016/j.ejca.2013.08.020
Publication status	Published - 2014
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ejca.2013.08.020

184 Citations
1 Letter

Reply: `Antitumor activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone.
Omlin, A., Pezaro, C. J., Zaidi, S., Lorente, D., Mukherji, D., Bianchini, D., Ferraldeschi, R., Sandhu, S. K., Dearnaley, D. P., Parker, C., Van As, N., De Bono, J. S. & Attard, G., 2014, In: British Journal of Cancer. 110, p. 267 - 268 2 p.
Research output: Contribution to journal › Letter › Other

Cite this

Bianchini, D., Lorente, D., Rodriguez-Vida, A., Omlin, A., Pezaro, C. J., Ferraldeschi, R., Zivi, A., Attard, G., Chowdhury, S., & De Bono, J. S. (2014). Antitumor activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. European Journal of Cancer, 50(1), 78-84. https://doi.org/10.1016/j.ejca.2013.08.020

@article{ce9aa9d02c5243698fc0af83be09abd8,

title = "Antitumor activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone.",

author = "Diletta Bianchini and David Lorente and Alejo Rodriguez-Vida and Aurelius Omlin and Pezaro, {Carmel Jo} and Roberta Ferraldeschi and Andrea Zivi and Gerhardt Attard and Simon Chowdhury and {De Bono}, {Johann S}",

year = "2014",

doi = "10.1016/j.ejca.2013.08.020",

language = "English",

volume = "50",

pages = "78--84",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier",

number = "1",

}

Bianchini, D, Lorente, D, Rodriguez-Vida, A, Omlin, A, Pezaro, CJ, Ferraldeschi, R, Zivi, A, Attard, G, Chowdhury, S & De Bono, JS 2014, 'Antitumor activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone.', European Journal of Cancer, vol. 50, no. 1, pp. 78-84. https://doi.org/10.1016/j.ejca.2013.08.020

Antitumor activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. / Bianchini, Diletta; Lorente, David; Rodriguez-Vida, Alejo et al.
In: European Journal of Cancer, Vol. 50, No. 1, 2014, p. 78-84.

Research output: Contribution to journal › Article › Research › peer-review

TY - JOUR

T1 - Antitumor activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone.

AU - Bianchini, Diletta

AU - Lorente, David

AU - Rodriguez-Vida, Alejo

AU - Omlin, Aurelius

AU - Pezaro, Carmel Jo

AU - Ferraldeschi, Roberta

AU - Zivi, Andrea

AU - Attard, Gerhardt

AU - Chowdhury, Simon

AU - De Bono, Johann S

PY - 2014

Y1 - 2014

U2 - 10.1016/j.ejca.2013.08.020

DO - 10.1016/j.ejca.2013.08.020

M3 - Article

SN - 0959-8049

VL - 50

SP - 78

EP - 84

JO - European Journal of Cancer

JF - European Journal of Cancer

IS - 1

ER -

Antitumor activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone.

UN SDGs

Access to Document

Research output

Reply: `Antitumor activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone.

Cite this